GENFLEET-B (02595) Shares Surge Nearly 8% in Early Trading; Investigational Oral Drug Proposed for Breakthrough Therapy Designation

Stock News

Sep 29

GENFLEET-B (02595) climbed nearly 8% in morning trading. As of press time, the stock was up 5.47% at HK$28.9, with turnover of HK$37.7862 million.

On the news front, the company's self-developed oral KRAS G12D inhibitor GFH375 has been proposed by the CDE for inclusion in the breakthrough therapy designation list for the treatment of KRAS G12D-mutant colorectal cancer. If it passes the public comment period, this will be the third breakthrough therapy designation for GFH375, following two previous designations for KRAS G12D-mutant non-small cell lung cancer and pancreatic cancer.

Notably, GENFLEET-B will hold an online investor call on October 15 to release preliminary research data on GFH375 in combination with cetuximab for the treatment of KRAS G12D-mutant solid tumors. In addition, preliminary clinical data for GFH276 monotherapy in RAS-mutant solid tumors has been selected as a Late-Breaking Abstract (LBA33) at the 2026 ESMO Congress, and the company will hold an online investor call on October 25 to discuss the data.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1156162380"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156162380\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156162380?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-29 11:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156162380","market":"nz","top_or_hot":-1,"title":"GENFLEET-B (02595) Shares Surge Nearly 8% in Early Trading; Investigational Oral Drug Proposed for Breakthrough Therapy Designation","media":"Stock News","content":"<p><b>GENFLEET-B</b> (<b>02595</b>) climbed nearly 8% in morning trading. As of press time, the stock was up 5.47% at HK$28.9, with turnover of HK$37.7862 million.<br><br>On the news front, the company's self-developed oral KRAS G12D inhibitor GFH375 has been proposed by the CDE for inclusion in the breakthrough therapy designation list for the treatment of KRAS G12D-mutant colorectal cancer. If it passes the public comment period, this will be the third breakthrough therapy designation for GFH375, following two previous designations for KRAS G12D-mutant non-small cell lung cancer and pancreatic cancer.<br><br>Notably, GENFLEET-B will hold an online investor call on October 15 to release preliminary research data on GFH375 in combination with cetuximab for the treatment of KRAS G12D-mutant solid tumors. In addition, preliminary clinical data for GFH276 monotherapy in RAS-mutant solid tumors has been selected as a Late-Breaking Abstract (LBA33) at the 2026 ESMO Congress, and the company will hold an online investor call on October 25 to discuss the data.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENFLEET-B (02595) Shares Surge Nearly 8% in Early Trading; Investigational Oral Drug Proposed for Breakthrough Therapy Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENFLEET-B (02595) Shares Surge Nearly 8% in Early Trading; Investigational Oral Drug Proposed for Breakthrough Therapy Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-29 11:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>GENFLEET-B</b> (<b>02595</b>) climbed nearly 8% in morning trading. As of press time, the stock was up 5.47% at HK$28.9, with turnover of HK$37.7862 million.<br><br>On the news front, the company's self-developed oral KRAS G12D inhibitor GFH375 has been proposed by the CDE for inclusion in the breakthrough therapy designation list for the treatment of KRAS G12D-mutant colorectal cancer. If it passes the public comment period, this will be the third breakthrough therapy designation for GFH375, following two previous designations for KRAS G12D-mutant non-small cell lung cancer and pancreatic cancer.<br><br>Notably, GENFLEET-B will hold an online investor call on October 15 to release preliminary research data on GFH375 in combination with cetuximab for the treatment of KRAS G12D-mutant solid tumors. In addition, preliminary clinical data for GFH276 monotherapy in RAS-mutant solid tumors has been selected as a Late-Breaking Abstract (LBA33) at the 2026 ESMO Congress, and the company will hold an online investor call on October 25 to discuss the data.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02595","symbol_name":"劲方医药-B","start_time":0,"source_url":"","article_id":"1156162380","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156162380","pubTimestamp":1790652676,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GENFLEET-B (02595) climbed nearly 8% in morning trading. As of press time, the stock was up 5.47% at HK$28.9, with turnover of HK$37.7862 million.On the news front, the company's self-developed oral...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","02595":"劲方医药-B","VXUS":"国际股票ETF-Vanguard","09939":"开拓药业-B","BK4588":"碎股","KCAI":"KraneShares China Alpha Index ETF","BK4585":"ETF&股票定投概念","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"GENFLEET-B (02595) 股价早盘飙升近 8%；拟用于突破性治疗指定的研究性口服药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02595":1,"VXUS":1,"09939":1,"KCAI":1},"content_text":"GENFLEET-B (02595) climbed nearly 8% in morning trading. As of press time, the stock was up 5.47% at HK$28.9, with turnover of HK$37.7862 million.On the news front, the company's self-developed oral KRAS G12D inhibitor GFH375 has been proposed by the CDE for inclusion in the breakthrough therapy designation list for the treatment of KRAS G12D-mutant colorectal cancer. If it passes the public comment period, this will be the third breakthrough therapy designation for GFH375, following two previous designations for KRAS G12D-mutant non-small cell lung cancer and pancreatic cancer.Notably, GENFLEET-B will hold an online investor call on October 15 to release preliminary research data on GFH375 in combination with cetuximab for the treatment of KRAS G12D-mutant solid tumors. In addition, preliminary clinical data for GFH276 monotherapy in RAS-mutant solid tumors has been selected as a Late-Breaking Abstract (LBA33) at the 2026 ESMO Congress, and the company will hold an online investor call on October 25 to discuss the data.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}